PMID- 33434602
OWN - NLM
STAT- MEDLINE
DCOM- 20210419
LR  - 20210419
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 172
DP  - 2021 Feb
TI  - Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral 
      semaglutide in patients with type 2 diabetes mellitus: A systematic review and 
      meta-analysis.
PG  - 108656
LID - S0168-8227(21)00009-7 [pii]
LID - 10.1016/j.diabres.2021.108656 [doi]
AB  - OBJECTIVES: To evaluate the efficacy and safety of the glucagon-like peptide-1 
      (GLP-1) receptor agonist (RA) oral semaglutide in the treatment of type 2 
      diabetes mellitus (T2DM) patients. METHODS: Randomized controlled trials 
      comparing oral semaglutide with placebo or other antihyperglycemic agents in T2DM 
      patients were identified by searching PubMed, Embase, Cochrane Library and 
      ClinicalTrials.gov. Risk ratios and mean differences with 95% confidence 
      intervals were used to synthesize the results. RESULTS: Ten relevant studies 
      involving 8,536 patients were finally included. Compared with placebo, oral 
      semaglutide significantly reduced hemoglobin A1c (HbA1c), body weight, fasting 
      plasma glucose, self-measured plasma glucose (SMPG), serious adverse events and 
      all-cause death and significantly increased the number of participants who 
      achieved HbA1c < 7.0%. Compared with active comparators, oral semaglutide 
      significantly reduced the level of HbA1c, body weight, and SMPG and significantly 
      increased the number of participants who achieved HbA1c < 7.0%. Compared with 
      placebo or active comparators, oral semaglutide did not increase the incidence of 
      adverse events, hypoglycemia (severe or blood glucose-confirmed symptomatic), 
      myocardial infarction, heart failure requiring hospitalization, stroke or acute 
      pancreatitis but did increase the incidence of nausea, diarrhea and vomiting. 
      CONCLUSIONS: Oral semaglutide has favorable efficacy and safety in the treatment 
      of T2DM patients. Oral semaglutide may be superior to liraglutide, dulaglutide, 
      empagliflozin and sitagliptin for T2DM patients who have obesity or poor 
      adherence to injectable GLP-1 RAs.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Li, Jingxin
AU  - Li J
AD  - Department of Chinese Pharmacy, Hebei Maternity Hospital, 27 Shifeng Road, Qiaoxi 
      District, Shijiazhuang 050051, Hebei Province, China.
FAU - He, Ke
AU  - He K
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang/Shijiazhuang 
      Obstetrics and Gynecology Hospital, 206 Zhongshan East Road, Changan District, 
      Shijiazhuang 050017, Hebei Province, China. Electronic address: hkwkc77@163.com.
FAU - Ge, Jun
AU  - Ge J
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang/Shijiazhuang 
      Obstetrics and Gynecology Hospital, 206 Zhongshan East Road, Changan District, 
      Shijiazhuang 050017, Hebei Province, China.
FAU - Li, Caixia
AU  - Li C
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang/Shijiazhuang 
      Obstetrics and Gynecology Hospital, 206 Zhongshan East Road, Changan District, 
      Shijiazhuang 050017, Hebei Province, China.
FAU - Jing, Zeng
AU  - Jing Z
AD  - Department of Pharmacy, The Fourth Hospital of Shijiazhuang/Shijiazhuang 
      Obstetrics and Gynecology Hospital, 206 Zhongshan East Road, Changan District, 
      Shijiazhuang 050017, Hebei Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210109
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - Administration, Oral
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucagon-Like Peptides/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Middle Aged
OTO - NOTNLM
OT  - Meta-analysis
OT  - Oral semaglutide
OT  - Randomized controlled trials
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/01/13 06:00
MHDA- 2021/04/20 06:00
CRDT- 2021/01/12 20:08
PHST- 2020/09/11 00:00 [received]
PHST- 2020/12/25 00:00 [revised]
PHST- 2021/01/06 00:00 [accepted]
PHST- 2021/01/13 06:00 [pubmed]
PHST- 2021/04/20 06:00 [medline]
PHST- 2021/01/12 20:08 [entrez]
AID - S0168-8227(21)00009-7 [pii]
AID - 10.1016/j.diabres.2021.108656 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2021 Feb;172:108656. doi: 10.1016/j.diabres.2021.108656. 
      Epub 2021 Jan 9.